River BioMedics combines cardiac biology knowledge with expertise in bio-engineering and human induced pluripotent stem cells (hiPSC) to develop 3D cardiac in vitro models for the discovery and development of novel cardiac drugs.

River BioMedics

We combine our cardiac biology knowhow with our expertise in bio-engineering and human induced pluripotent stem cells (hiPSC) to develop 3D cardiac in vitro models for the discovery and development of novel cardiac drugs.

KIKK Capital

OostNL

BioGeneration Ventures

River BioMedics 

We had a great time at EUROoCS in Milan last week! Amélie BOCQUET and Chloë Kaal showcased our work in a poster session. We enjoyed the many inspiring talks and all the connections we made.

Did you miss us there? Feel free to connect now!

#closertotheheart #3Dheartmodels #drugdiscovery

We are excited to share that our CSO, Marcelo Catarino Ribeiro, will attend the Oxford Global - 3D Cell Culture and Organ Modelling 2024 conference in London next week. He'll be part of two panel discussions and will share our work on cardiac target validation:

📌 18th of March 13.40 - Panel Discussion: Validation Of Organ Models
📌 19th of March 11.40 - Panel Discussion: Overcoming Challenges Of Scalability In Organoid Modelling
📌 19th of March 12.40 - Presentation: Modeling HFpEF Cardiac Stiffness Using Human 3D Cardiac Tissues And Its Application In Target Validation

Can't make it? Check out our 3D cardiac models at RiverBioMedics.com or contact us! 

#OxfordGlobal2024 #closertotheheart #3Dheartmodels #drugdiscovery

We are proud to share our latest publication in Advanced Healthcare Materials: Micro-Engineered Heart Tissues On-Chip with Heterotypic Cell Composition Display Self-Organization and Improved Cardiac Function.

Many thanks to all those that contributed!

Discover all of our work at our website: https://lnkd.in/eghxaAXZ

#closertotheheart #3Dheartmodels #drugdiscovery

Find us at #BioEquityEurope 12-14th of May to hear more about our disease modifying approach to HFpEF and our 3D cardiac strip technology!

#closertotheheart #3Dheartmodels #drugdiscovery

We are attending EUROoCS in Milan this week (3rd-5th of July). 

Find us at the poster session on Friday (12:30-14:00):

📌 F-035 - Amélie BOCQUET - Rapid-prototyped macro-valves for fluidic control of μ3Dcardiac tissues-on-chip

📌 F-039 - Chloë Kaal - Maturation induced Titin isoform switching in 3D cardiac stiffening model

Can’t make it? Check out our 3D cardiac models at RiverBioMedics.com or contact us!

#EUROoCS2024 #closertotheheart #3Dheartmodels #drugdiscovery

Our team will be present at ELRIG UK DRUG DISCOVERY 2023 and we are very much looking forward to seeing you there. 

Our CEO, Nicky Cooper, is co-charing one of the sessions TRANSLATING IDEAS INTO THERAPIES:

"Join me in person, for free, on 18 - 19 October 2023. I'm looking forward to co-chairing a session at this meeting hosted by ELRIG UK at the at ACC, Liverpool."

#ELRIG #ELRIGDD23 #DrugDiscovery #DD2023 #networking #closertotheheart #3Dheartmodels

Metric
Company Name	River BioMedics
Symbol
MSH ID	COM:RIVERBIOMEDICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	NL
Stage	Seed
Employee Count	16
Website	riverbiomedics.com
LinkedIn	river-biomedics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	75
Web Traffic Growth
Valuation
Raised Capital	2.04M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:RIVERBIOMEDICS

River BioMedics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue